{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:08:47Z","timestamp":1778677727770,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["387509280"],"award-info":[{"award-number":["387509280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1350"],"award-info":[{"award-number":["SFB 1350"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001652","name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.diabres.2021.108691","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T23:33:24Z","timestamp":1612481604000},"page":"108691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CD161a-positive natural killer (NK) cells and \u03b1-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection"],"prefix":"10.1016","volume":"173","author":[{"given":"Franziska","family":"Schmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"B\u00fcttner-Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von H\u00f6rsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-065X.1998.tb01571.x","article-title":"The structure and function of CD26 in the T-cell immune response","volume":"161","author":"Morimoto","year":"1998","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.diabres.2021.108691_b0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/44.5.8627002","article-title":"Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice","volume":"44","author":"Mentzel","year":"1996","journal-title":"J Histochemistry Cytochemistry : Official J Histochemistry Soc"},{"key":"10.1016\/j.diabres.2021.108691_b0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.peptides.2014.05.006","article-title":"Soluble DPP4 originates in part from bone marrow cells and not from the kidney","volume":"57","author":"Wang","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.diabres.2021.108691_b0020","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.diabres.2021.108691_b0025","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.diabres.2021.108691_b0030","doi-asserted-by":"crossref","first-page":"F681","DOI":"10.1152\/ajprenal.00075.2012","article-title":"DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury","volume":"303","author":"Glorie","year":"2012","journal-title":"Am J Physiology Renal Physiology"},{"issue":"8","key":"10.1016\/j.diabres.2021.108691_b0035","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/TP.0b013e31819e04c3","article-title":"Primary graft dysfunction in lung transplantation: the role of CD26\/dipeptidylpeptidase IV and vasoactive intestinal peptide","volume":"87","author":"Zhai","year":"2009","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.diabres.2021.108691_b0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/nep.12618","article-title":"Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes","volume":"21","author":"Gangadharan Komala","year":"2016","journal-title":"Nephrology (Carlton, Vic)"},{"issue":"3","key":"10.1016\/j.diabres.2021.108691_b0045","first-page":"403","article-title":"Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice","volume":"1862","author":"Marques","year":"2018","journal-title":"BBA"},{"key":"10.1016\/j.diabres.2021.108691_b0050","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/ki.2015.103","article-title":"Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition","volume":"88","author":"Shi","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.41058","article-title":"Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis","volume":"72","author":"Soare","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.diabres.2021.108691_b0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtcvs.2016.10.080","article-title":"Anti-inflammatory effects on ischemia\/reperfusion-injured lung transplants by the cluster of differentiation 26\/dipeptidylpeptidase 4 (CD26\/DPP4) inhibitor vildagliptin","volume":"153","author":"Jang","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.diabres.2021.108691_b0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.healun.2006.11.601","article-title":"Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia\/reperfusion injury after extended ischemia","volume":"26","author":"Zhai","year":"2007","journal-title":"J Heart Lung Transplant"},{"issue":"1-2","key":"10.1016\/j.diabres.2021.108691_b0070","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0041-1345(98)01812-0","article-title":"CD26\/DPP IV-mediated modulation of acute rejection","volume":"31","author":"Korom","year":"1999","journal-title":"Transpl Proc"},{"issue":"6","key":"10.1016\/j.diabres.2021.108691_b0075","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"issue":"3","key":"10.1016\/j.diabres.2021.108691_b0080","doi-asserted-by":"crossref","DOI":"10.1515\/CCLM.2009.064","article-title":"Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions","volume":"47","author":"Frerker","year":"2009","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"10.1016\/j.diabres.2021.108691_b0085","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1093\/ndt\/gfq230","article-title":"Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat","volume":"25","author":"Vogelbacher","year":"2010","journal-title":"Nephrology, Dialysis, Transplantation : Official Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc"},{"key":"10.1016\/j.diabres.2021.108691_b0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diabres.2018.07.009","article-title":"Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin","volume":"143","author":"Luippold","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.diabres.2021.108691_b0090","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1681\/ASN.2017010079","article-title":"Complement recognition pathways in renal transplantation","volume":"28","author":"Nauser","year":"2017","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"2","key":"10.1016\/j.diabres.2021.108691_b0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The global epidemiology of diabetes and kidney disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.diabres.2021.108691_b0100","article-title":"Review of newer antidiabetic agents for diabetes management in kidney transplant recipients","volume":"1060028020951955","author":"Anderson","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.diabres.2021.108691_b0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2174\/1573399815666190321144310","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis","volume":"16","author":"Abdelaziz","year":"2020","journal-title":"Curr Diabetes Rev"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0110","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.intimp.2015.07.022","article-title":"Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin","volume":"28","author":"Ateyya","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3803\/EnM.2016.31.1.161","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study","volume":"31","author":"Bae","year":"2016","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"key":"10.1016\/j.diabres.2021.108691_b0120","doi-asserted-by":"crossref","first-page":"107864","DOI":"10.1016\/j.diabres.2019.107864","article-title":"Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study","volume":"156","author":"Guardado-Mendoza","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ajt.12518","article-title":"Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation\u2013a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Haidinger","year":"2014","journal-title":"Am J Transplantation : Official J Am Soc Transplantation Am Soc Transplant Surgeons"},{"key":"10.1016\/j.diabres.2021.108691_b0130","doi-asserted-by":"crossref","first-page":"108604","DOI":"10.1016\/j.diabres.2020.108604","article-title":"Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: a systematic review and meta-analysis","volume":"172","author":"Oikonomaki","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.diabres.2021.108691_b0135","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation","volume":"29","author":"Strom Halden","year":"2014","journal-title":"Nephrology, Dialysis, Transplantation : Official Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2021.108691_b0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.diabres.2021.108691_b0145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10517-016-3447-6","article-title":"Effect of linagliptin on structural changes in the kidney in experimental type 2 diabetes mellitus","volume":"161","author":"Gavrilova","year":"2016","journal-title":"Bull Exp Biol Med"},{"issue":"33","key":"10.1016\/j.diabres.2021.108691_b0150","doi-asserted-by":"crossref","first-page":"54821","DOI":"10.18632\/oncotarget.18962","article-title":"DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.diabres.2021.108691_b0155","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/bph.13822","article-title":"Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury","volume":"174","author":"Reichetzeder","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabres.2021.108691_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8912768","article-title":"Dipeptidyl peptidase 4 inhibition ameliorates chronic kidney disease in a model of salt-dependent hypertension","volume":"2019","author":"Cappetta","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/aps.2014.98","article-title":"Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors","volume":"36","author":"Chang","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.diabres.2021.108691_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5284963","article-title":"Sitagliptin accelerates endothelial regeneration after vascular injury independent from GLP1 receptor signaling","volume":"2018","author":"Remm","year":"2018","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.diabres.2021.108691_b0175","doi-asserted-by":"crossref","first-page":"113951","DOI":"10.1016\/j.bcp.2020.113951","article-title":"Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK\/SIRT1\/Nrf2 signaling pathway","volume":"177","author":"Chen","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.diabres.2021.108691_b0180","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MNH.0000000000000291","article-title":"Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects","volume":"26","author":"Takagaki","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/0886022X.2017.1279553","article-title":"Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis","volume":"39","author":"Uchida","year":"2017","journal-title":"Ren Fail"},{"issue":"1-3","key":"10.1016\/j.diabres.2021.108691_b0195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.regpep.2010.08.007","article-title":"Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes","volume":"166","author":"Vaghasiya","year":"2011","journal-title":"Regul Pept"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-physiol-022516-034219","article-title":"Macrophages in renal injury and repair","volume":"79","author":"Huen","year":"2017","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.diabres.2021.108691_b0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1479-5876-11-270","article-title":"Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction","volume":"11","author":"Chen","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.diabres.2021.108691_b0210","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/00007890-199705270-00021","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients","volume":"63","author":"Korom","year":"1997","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.diabres.2021.108691_b0215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjh.12378","article-title":"Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody","volume":"162","author":"Hatano","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.diabres.2021.108691_b0220","doi-asserted-by":"crossref","first-page":"e82639","DOI":"10.1371\/journal.pone.0082639","article-title":"Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A\/VEGFR-2 signaling pathway","volume":"8","author":"Samikannu","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:09:37Z","timestamp":1778674177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"alternative-id":["S0168822721000449"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108691","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD161a-positive natural killer (NK) cells and \u03b1-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108691"}}